MIRA INFORM REPORT
|
Report No. : |
342799 |
|
Report Date : |
30.09.2015 |
IDENTIFICATION DETAILS
|
Name : |
CHANGZHOU PHARMACEUTICAL FACTORY |
|
|
|
|
Registered Office : |
No. 518 Laodong East Road, Changzhou Jiangsu Province 213018 Pr |
|
|
|
|
Country : |
China |
|
|
|
|
Financial As on : |
31.12.2014 |
|
|
|
|
Date of Incorporation : |
14.12.2001 |
|
|
|
|
Com. Reg. No.: |
320400000002679 |
|
|
|
|
Legal Form : |
Limited Liability Company |
|
|
|
|
Line of Business : |
Subject is engaged in manufacturing and selling drugs. |
|
|
|
|
No. of Employee : |
1,261 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made on
e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
CHINA ECONOMIC OVERVIEW
Since the late 1970s China has moved from a closed, centrally planned system to a more market-oriented one that plays a major global role - in 2010 China became the world's largest exporter. Reforms began with the phasing out of collectivized agriculture, and expanded to include the gradual liberalization of prices, fiscal decentralization, increased autonomy for state enterprises, growth of the private sector, development of stock markets and a modern banking system, and opening to foreignTRADE and investment. China has implemented reforms in a gradualist fashion. In recent years, China has renewed its support for state-owned enterprises in sectors considered important to "economic security," explicitly looking to foster globally competitive industries. The restructuring of the economy and resulting efficiency gains have contributed to a more than tenfold increase in GDP since 1978. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, China in 2014 stood as the largest economy in the world, surpassing the US for the first time in modern history. Still, China's per capita income is below the world average.
After keeping its currency tightly linked to the US dollar for years, in July 2005 China moved to an exchange rate system that references a basket of currencies. From mid 2005 to late 2008 cumulative appreciation of the renminbi against the US dollar was more than 20%, but the exchange rate remained virtually pegged to the dollar from the onset of the globalFINANCIAL crisis until June 2010, when Beijing allowed resumption of a gradual appreciation. In 2014 the People’s Bank of China (PBOC) doubled the dailyTRADING band within which the RMB is permitted to fluctuate.
The Chinese government faces numerous economic challenges, including: (a) reducing its high domestic savings rate and correspondingly low domestic consumption; (b) facilitating higher-wage job opportunities for the aspiring middle class, including rural migrants and increasing numbers of college graduates; (c) reducing corruption and other economic crimes; and (d) containing environmental damage and social strife related to the economy's rapid transformation. Economic development has progressed further in coastal provinces than in the interior, and by 2014 more than 274 million migrant workers and their dependents had relocated to urban areas to find work. One consequence of population control policy is that China is now one of the most rapidly aging countries in the world. Deterioration in the environment - notably air pollution, soil erosion, and the steady fall of the water table, especially in the North - is another long-term problem. China continues to lose arable land because of erosion and economic development. The Chinese government is seeking to add energy production capacity from sources other than coal andOIL, focusing on nuclear and alternative energy development.
Several factors are converging to slow China's growth, including debt overhang from its credit-fueled stimulus program, industrial overcapacity, inefficient allocation of capital by state-owned banks, and the slow recovery of China's trading partners. The government's 12th Five-Year Plan, adopted in March 2011 and reiterated at the Communist Party's "Third Plenum" meeting in November 2013, emphasizes continued economic reforms and the need to increase domestic consumption in order to make the economy less dependent in the future on fixed investments, exports, and heavy industry. However, China has made only marginal progress toward these rebalancing goals. The new government of President XI Jinping has signaled a greater willingness to undertake reforms that focus on China's long-term economic health, including giving the market a more decisive role in allocating resources. In 2014 China agreed to begin limiting carbon dioxide emissions by 2030. China also implemented several economic reforms in 2014, including passing legislation to allow local governments to issue bonds, opening several state-owned enterprises to further private investment, loosening the one-child policy, passing harsher pollution fines, and cutting administrative red tape.
|
Source
: CIA |
Company
name and address
CHANGZHOU PHARMACEUTICAL FACTORY
NO. 518 LAODONG EAST ROAD, CHANGZHOU
JIANGSU PROVINCE 213018 PR CHINA
TEL: 86 (0) 519-88811641/88801672
FAX: 86 (0) 519-88256855
EXECUTIVE
SUMMARY
Date of Registration : december 14, 2001
REGISTRATION NO. : 320400000002679
LEGAL FORM : Limited Liability Company
REGISTERED CAPITAL : CNY
108,000,000
staff : 1,261
BUSINESS CATEGORY : MANUFACTURING
& TRADING
Revenue : cny 655,460,000 (AS OF DEC. 31, 2014)
EQUITIES : cny 744,750,000 (AS OF DEC. 31, 2014)
WEBSITE : www.czzyc.com
E-MAIL : changyao@czpharma.com
PAYMENT : AVERAGE
MARKET CONDITION : COMPETITIVE
FINANCIAL CONDITION : fairly good
OPERATIONAL TREND : fairly STEADY
GENERAL REPUTATION : AVERAGE
EXCHANGE RATE : CNY 6.37 = USD 1
ADOPTED ABBREVIATIONS (AS FOLLOWS)
SC - Subject Company
(the company inquired by you)
N/A – Not available
CNY – China Yuan Ren
Min Bi
OPERATIONAL
TREND & GENERAL REPUTATION
This section aims at indicating the relative positions of SC in respect
of its operational trend & general reputation
Operational Trend:- General
Reputation:-
Upward Excellent
Steady Good
Fairly Steady Fairly
Good
Ordinary Average
Fair Fair
Stagnant Detrimental
Downward Not
known
Not known Not
yet be determined
Not yet be determined
LEGAL
STATUS & HISTORY
SC was established
as a limited liabilities company of PRC with State Administration of Industry
& Commerce (SAIC) under registration No.: 320400000002679
on December 14, 2001.
SC’s Organization Code Certificate No.:
13715849-0
SC’s Tax No.: 320400137158490
SC’s registered capital: CNY 108,000,000
SC’s paid-in capital: CNY 108,000,000
Registration Change Record:-
No significant changes of SC have been noted
in SAIC since its incorporation.
Current Co search indicates SC’s shareholders & chief executives are
as follows:-
|
Name of Shareholder (s) |
% of Shareholding |
|
Changzhou Pharmaceutical Co., Ltd. |
77.78 |
|
Wang Sunan |
2.78 |
|
Xu Ruiqun |
1.39 |
|
Li Huifen |
1.39 |
|
Other individuals |
16.66 |
SC’s Chief Executives:-
|
Position |
Name |
|
Legal Representative and Chairman |
Zhao Yuqiu |
|
Vice Chairman |
Wang Sunan |
|
General Manager |
Tang Jian |
|
Director |
Lu Qiang |
|
Li Huifen |
|
|
Zhang Ziqiang |
|
|
Zhang Huaipei |
|
|
Supervisor |
Lu Wenxian |
|
Wang Bing |
|
|
Yu Shoumin |
RECENT
DEVELOPMENT
No recent development was found during our checks at present.
SHAREHOLDER
CHART & BACKGROUND
Name %
of Shareholding
Changzhou Pharmaceutical Co., Ltd. 77.78
Wang Sunan 2.78
Xu Ruiqun 1.39
Li Huifen 1.39
Other individuals 16.66
Changzhou
Pharmaceutical Co., Ltd.
-------------------------------------------------
Date of Registration: November 1, 1993
Registration No.: 320000000003319
Registered Capital: CNY 78,790,253
MANAGEMENT
Zhao Yuqiu, Legal Representative and Chairman
---------------------------------------------------------------------------
Ø
Gender: M
Ø
ID# 321086195908230016
Ø
Age: 56
Ø
Nationality: China
Ø Qualification:
University
Ø Working experience
(s):
At present, working in SC as legal
representative and chairman
Wang
Sunan, Vice Chairman
-------------------------------------------------
Ø
Gender: M
Ø
Nationality: China
Ø Qualification:
University
Ø Working experience
(s):
At present, working in SC as vice chairman
Tang
Jian, General Manager
----------------------------------------------
Ø
Gender: M
Ø
Nationality: China
Ø Qualification:
University
Ø Working experience
(s):
At present, working in SC as general manager
Director
----------
Lu Qiang
Li Huifen
Zhang Ziqiang
Zhang Huaipei
Supervisor
--------------
Lu Wenxian
Wang Bing
Yu Shoumin
BUSINESS
OPERATION
SC’s registered business scope includes manufacturing drugs,
multivitamin soft capsule health products; operating and acting as an agent of
importing and exporting various kinds of commodities and technology, excluding
the goods forbidden by the government.
SC is mainly
engaged in manufacturing and selling drugs.
SC’s products mainly include:
Hydrochlorothiazide
Chlorothiazide
Captopril
Enalapril Maleate
Doxycycline
Hyclate
Doxycycline
Monohydrate
Thalidomide
Almitrine
Dimesylate
Folic Acid
Rosuvastatin
Calcium
SC sources its materials 100% from domestic market, mainly Jiangsu. SC sells 80% of its products in domestic market, and 20% to overseas market, mainly USA, Europe, Mid East, Southeast Asia, etc.
The buying terms
of SC include Check, T/T and Credit of 30-60 days. The payment terms of SC include
T/T, L/C and Credit of 30-60 days.
*Major Customers:
==============
Icc Chemical
Corporation
New Chemic (U.S.)
Inc.
Teva Canada
Limited
Staff & Office:
--------------------------
SC is known
to have approx. 1,261 staff
at present.
SC owns an area as
its operating office and factory, but the detailed information is unknown.
RELATED
COMPANY
SC is known to have 3
subsidiaries at present:
Nantong
Changyou Pharmaceutical Technology Co., Ltd.
Changzhou Wuxin Pharmaceutical Co., Ltd.
Chifeng Keyuan Investment & Development Co., Ltd.
PAYMENT
Overall payment appraisal:
( ) Excellent ( ) Good (X) Average ( ) Fair ( ) Poor ( ) Not yet be determined
The appraisal serves as a reference to reveal SC's payments habits and ability
to pay. It is based on the 3 weighed
factors: Trade payment experience (through current enquiry with SC's
suppliers), our delinquent payment and our debt collection record concerning
SC.
Trade payment experience: SC did not
provide any name of trade/service suppliers and we have no other sources to
conduct the enquiry at present.
Delinquent payment record: None in our
database.
Debt collection record: No overdue amount
owed by SC was placed to us for collection within the last 6 years.
BANKING
The bank
information of SC is not filed in SAIC.
FINANCIALS
Financial Summary
|
Unit: CNY’000 |
As
of Dec. 31, 2013 |
As
of Dec. 31, 2014 |
|
Total assets |
875,220 |
942,480 |
|
|
------------- |
------------- |
|
Total
liabilities |
181,870 |
197,730 |
|
Equities |
693,350 |
744,750 |
|
|
------------- |
------------- |
|
Revenue |
654,660 |
655,460 |
|
Profit before
tax |
148,270 |
141,260 |
|
Less: profit tax |
21,260 |
20,710 |
|
Profits |
127,010 |
120,550 |
Important Ratios
=============
|
|
As
of Dec. 31, 2013 |
As
of Dec. 31, 2014 |
|
*Liabilities
to assets |
0.21 |
0.21 |
|
*Net profit
margin (%) |
19.40 |
18.39 |
|
*Return on
total assets (%) |
14.51 |
12.79 |
|
*Revenue /
Total assets |
0.75 |
0.70 |
FINANCIAL
COMMENTS
PROFITABILITY: FAIRLY
GOOD
l The revenue of SC
appears fairly good in its line.
l SC’s net profit
margin is fairly good.
l SC’s return on
total assets is fairly good.
LIQUIDITY: AVERAGE
l
SC’s revenue is in an average level, comparing with
the size of its total assets.
LEVERAGE: AVERAGE
l
The debt ratio of SC is low.
l
The risk for SC to go bankrupt is average.
Overall financial
condition of the SC: Fairly Good.
CONCLUSIONS
SC is considered large-sized in its line with fairly good financial
conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.66.18 |
|
|
1 |
Rs.100.46 |
|
Euro |
1 |
Rs.74.61 |
INFORMATION DETAILS
|
Analysis Done by
: |
DIV |
|
|
|
|
Report Prepared
by : |
ANK |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.